ImmunoGen, Inc. v. Stewart, No. 23-1762 (Fed. Cir. Mar. 6, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This case, arising from a civil action to obtain a patent under 35 U.S.C. § 145, returns to this court following a re- mand in ImmunoGen, Inc. v. Hirshfeld, No. 2021-1939, 2022 WL 885774 (Fed. Cir. Mar. 25, 2022) (“ ImmunoGen II”). Following vacatur of the district court’s grant of sum- mary judgment in favor of the government, the case pro- ceeded to a bench trial on the question whether ImmunoGen, Inc. is entitled to a patent for the invention claimed in U.S. Patent Application 14/509,809 (“the ’809 application”).